|Headquarters||San Diego, California, United States|
|Daniel M. Bradbury|
|Revenue||US$758M (FY 2009)|
|US$-173M (FY 2009)|
|US$-186M (FY 2009)|
|Total assets||US$1.73B (FY 2009)|
|Total equity||US$423M (FY 2009)|
Number of employees
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.
In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.
In December 2013, Amylin was acquired by AstraZeneca.
- "Company Profile for Amylin Pharmaceuticals Inc (AMLN)". Retrieved 2008-10-21.
- Amylin Pharmaceuticals (AMLN) annual SEC income statement filing via Wikinvest.
- Amylin Pharmaceuticals (AMLN) annual SEC balance sheet filing via Wikinvest.
- Lipodystrophy Orphan Drug Program. Amylin Pharmaceuticals.
- U.S. Food and Drug Administration (25 February 2014). "FDA approves Myalept to treat rare metabolic disease". News & Events: Press Announcements. Retrieved 22 June 2015.
- Shannon Pettypiece (3 July 2012). "Bristol's Amylin Deal Heralds Acquisition Hunger". Bloomberg.com. Retrieved 21 February 2015.
- Allison Connolly (19 December 2013). "AstraZeneca to Acquire Bristol Stake in Diabetes Venture". Bloomberg.com. Retrieved 21 February 2015.